Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-1809
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-1809 is an investigational small molecule drug that was developed by Merck & Co for the treatment of hypertension and other cardiovascular disorders. It was designed as an oral agent and underwent phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics. The goal of these studies included identifying a dose with similar pharmacokinetic properties to 100 mg losartan, a well-known angiotensin II receptor antagonist used in hypertension. However, the specific mechanism of action for MK-1809 remains unknown or undisclosed. Development did not progress beyond phase 1 clinical trials[1][2][4].
Beyond the preview
Go deeper on MK-1809.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-1809.